Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23615415 | 1.00 | GAA (0.46) | GAAALDH1A1LMNAGLATHRB | |
| SCHEMBL19647069 | 1.00 | GAA (0.46) | GAAALDH1A1LMNAGLATHRB | |
| SCHEMBL20160081 | 0.90 | ALDH1A1 (0.53) | GAAALDH1A1LMNATHRBCYP2C9 | |
| SCHEMBL20346848 | 0.90 | ALDH1A1 (0.53) | GAAALDH1A1LMNATHRBCYP2C9 | |
| SCHEMBL903575 | 0.90 | ALDH1A1 (0.53) | GAAALDH1A1LMNATHRBCYP2C9 | |
| Trifluoroacetic Acid SCHEMBL13731716 | 0.86 | ALDH1A1 (0.48) | GAAALDH1A1LMNATHRBCYP2C9 | |
| SCHEMBL14962706 | 0.85 | ATM (0.51) | GAAALDH1A1LMNAGLATHRB | |
| SCHEMBL903526 | 0.83 | ALDH1A1 (0.45) | ALDH1A1THRBCYP2C9CYP2C19HSD17B10 | |
| SCHEMBL16197554 | 0.83 | MME (0.47) | ALDH1A1LMNATHRBCYP2C9CYP2C19 | |
| SCHEMBL15292153 | 0.83 | MME (0.47) | ALDH1A1LMNATHRBCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3327027-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-07-07 | — | — | EP | disclosed |
| EP-3327027-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-3327027-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3327027-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | Pfizer Inc (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2780039-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2780039-B9 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2780039-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| EP-2780039-B1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9249186-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9249186-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. | 2014-12-11 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8828401-B2 | Cytotoxic peptides and antibody drug conjugates thereof | PFIZER INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2013072813-A2 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363452-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | GAA 1084/4885ALDH1A1 3253/4885LMNA 4369/4885 |
| US-20130129753-A1 | CYTOTOXIC PEPTIDES AND ANTIBODY DRUG CONJUGATES THEREOF | NGLY1, CD47, CD81 | GAA 1084/4885ALDH1A1 3253/4885LMNA 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.